<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02828917</url>
  </required_header>
  <id_info>
    <org_study_id>JNIR01</org_study_id>
    <nct_id>NCT02828917</nct_id>
  </id_info>
  <brief_title>MedJ-01 Ridaforolimus Eluting Coronary Stent System Trial (JNIR)</brief_title>
  <acronym>JNIR</acronym>
  <official_title>Multi-center Study for Evaluating the Safety and Efficacy of the MedJ-01 Ridaforolimus Eluting Coronary Stent System (MedJ-01) In Coronary Stenosis Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medinol Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medinol Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      MedJ-01 Ridaforolimus Eluting Coronary Stent System is a single use device/drug combination&#xD;
      product comprising:&#xD;
&#xD;
        -  A mounted Cobalt Chromium (CoCr) alloy based stent&#xD;
&#xD;
        -  A Rapid Exchange (RX) Coronary System Delivery System&#xD;
&#xD;
        -  A Poly n-butyl methacrylate (PBMA) and CarboSil®Polymer matrix coating&#xD;
&#xD;
        -  Ridaforolimus drug - CAS Registry Number: 572924-54-0 MedJ-01 is indicated for improving&#xD;
           coronary luminal diameter in patients with symptomatic heart disease due to lesions in&#xD;
           vessels with reference diameters of 2.5 mm to 4.25 mm, including complex lesions.&#xD;
&#xD;
      JNIR01 is aimed at assessing TLF at one year with the MedJ-01 stent in a Japanese patient&#xD;
      population to show equivalence to the results of the BIONICS Trial.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study aims to evaluate MedJ-01 safety and efficacy for de novo or restenosis lesion with&#xD;
      target vessel diameter of 2.5mm to 4.25, for subjects undergoing coronary artery stent&#xD;
      implantation. The target population is subjects undergoing PCI for angina (stable or&#xD;
      unstable), silent ischemia (in absence of symptoms a visually estimated target lesion&#xD;
      diameter stenosis of ≥70%, a positive non-invasive stress test, or FFR ≤0.80 must be&#xD;
      present), NSTEMI, and recent subacute STEMI (&gt;72 hours from initial presentation and stable).&#xD;
      Complex lesions are allowed. A maximum of two target vessels and two lesions per vessel may&#xD;
      be treated (two lesions separated by up to 10 mm that can be covered by a single stent are&#xD;
      considered as one lesion); the total planned study stenting in the coronary tree cannot&#xD;
      exceed 100 mm.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">January 16, 2017</start_date>
  <completion_date type="Anticipated">February 2022</completion_date>
  <primary_completion_date type="Actual">June 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Target Lesion Failure (TLF)</measure>
    <time_frame>12 months</time_frame>
    <description>TLF is defined as the composite of cardiac death, target vessel-related myocardial infarction, or ischemia-driven target lesion revascularization.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Device Success at Time of Baseline Procedure</measure>
    <time_frame>30 days, 6 months, and 1, 2, 3, 4 and 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lesion Success at Time of Baseline Procedure</measure>
    <time_frame>30 days, 6 months, and 1, 2, 3, 4 and 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Procedure Success at Time of Baseline Procedure</measure>
    <time_frame>30 days, 6 months, and 1, 2, 3, 4 and 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TLF</measure>
    <time_frame>30 days, 6 months, and 2, 3, 4 and 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major Adverse Cardiac Events (MACE)</measure>
    <time_frame>30 days, 6 months, and 1, 2, 3, 4 and 5 years</time_frame>
    <description>MACE is the composite rate of cardiac death, any MI or ischemia-driven TLR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target Vessel Failure (TVF)</measure>
    <time_frame>30 days, 6 months, and 1, 2, 3, 4 and 5 years</time_frame>
    <description>the composite rate of death, target vessel related MI or ischemia-driven TVR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All-cause Mortality</measure>
    <time_frame>30 days, 6 months, and 1, 2, 3, 4 and 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac Death</measure>
    <time_frame>30 days, 6 months, and 1, 2, 3, 4 and 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myocardial Infarction</measure>
    <time_frame>30 days, 6 months, and 1, 2, 3, 4 and 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target Vessel Related MI</measure>
    <time_frame>30 days, 6 months, and 1, 2, 3, 4 and 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ischemia-driven TLR</measure>
    <time_frame>30 days, 6 months, and 1, 2, 3, 4 and 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ischemia-driven TVR</measure>
    <time_frame>30 days, 6 months, and 1, 2, 3, 4 and 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stent Thrombosis</measure>
    <time_frame>30 days, 6 months, and 1, 2, 3, 4 and 5 years</time_frame>
    <description>ARC definite and probable</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">104</enrollment>
  <condition>de Novo or Restenosis Lesions</condition>
  <arm_group>
    <arm_group_label>MedJ-01 drug eluting stent</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MedJ-01 Ridaforolimus eluting coronary stent system</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>MedJ-01 Ridaforolimus Eluting Coronary Stent System</intervention_name>
    <arm_group_label>MedJ-01 drug eluting stent</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patient with indication for PCI including angina (stable/unstable), silent ischemia&#xD;
             (in absence of symptoms a visually estimated target lesion diameter stenosis of ≥70%,&#xD;
             a positive non-invasive stress test, or FFR ≤0.80 must be present), NSTEMI, or recent&#xD;
             subacute STEMI. For subacute STEMI the time of presentation to the first treating&#xD;
             hospital, whether a transfer facility or the study hospital, must be &gt;72 hours prior&#xD;
             to enrollment and enzyme levels (CK-MB or Troponin) demonstrating that either or both&#xD;
             enzyme levels have peaked.&#xD;
&#xD;
          2. Non-target vessel PCI are allowed prior to enrollment depending on the time interval&#xD;
             and conditions as follows:&#xD;
&#xD;
               -  During Baseline Procedure:&#xD;
&#xD;
                    -  PCI of non-target vessels performed during the baseline procedure itself&#xD;
                       immediately prior to enrollment if successful and uncomplicated defined as:&#xD;
                       &lt;50% visually estimated residual diameter stenosis, TIMI Grade 3 flow, no&#xD;
                       dissection ≥ NHLBI type C, no perforation, no persistent ST segment changes,&#xD;
                       no prolonged chest pain, no TIMI major or BARC type 3 bleeding.&#xD;
&#xD;
                    -  Less than 24 hours prior to Baseline Procedure:&#xD;
&#xD;
               -  Not allowed (see exclusion criterion #2).&#xD;
&#xD;
                    -  24 hours-30 days prior to Baseline Procedure:&#xD;
&#xD;
                    -  PCI of non-target vessels 24 hours to 30 days prior to enrollment if&#xD;
                       successful and uncomplicated as defined above.&#xD;
&#xD;
               -  In addition, in cases where non-target vessel PCI has occurred 24-72 hours prior&#xD;
                  to the baseline procedure, at least 2 sets of cardiac biomarkers must be drawn at&#xD;
                  least 6 and 12 hours after the non-target vessel PCI.&#xD;
&#xD;
               -  If cardiac biomarkers are initially elevated above the local laboratory upper&#xD;
                  limit of normal, serial measurements must demonstrate that the biomarkers are&#xD;
                  falling.&#xD;
&#xD;
                    -  Over 30 days prior to Baseline Procedure:&#xD;
&#xD;
                    -  PCI of non-target vessels performed greater than 30 days prior to procedure&#xD;
                       whether or not successful and uncomplicated.&#xD;
&#xD;
          3. Patient is willing and able to provide informed written consent and comply with&#xD;
             follow-up visits and testing schedule.&#xD;
&#xD;
             Angiographic inclusion criteria (visual estimate):&#xD;
&#xD;
          4. Target lesion(s) must be located in a native coronary artery with visually estimated&#xD;
             diameter of ≥2.5 mm to ≤4.25 mm.&#xD;
&#xD;
          5. Complex lesions are allowed including calcified lesions (lesion preparation with&#xD;
             scoring/cutting and rotational atherectomy are allowed), presence of thrombus that is&#xD;
             non-occlusive and does not require thrombectomy, CTO, bifurcationlesions (except&#xD;
             planned dual stent implantation), ostial RCA lesions, tortuous lesions, bare metal&#xD;
             stent restenotic lesions, protected left main lesions.&#xD;
&#xD;
          6. Overlapping stents are allowed with the investigational device (MedJ-01).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. STEMI within 72 hours (subacute) of initial time of presentation to the first treating&#xD;
             hospital, whether at a transfer facility or the study hospital or in whom enzyme&#xD;
             levels (either CK-MB or Troponin) have not peaked.&#xD;
&#xD;
          2. PCI within the 24 hours preceding the baseline procedure.&#xD;
&#xD;
          3. Non-target lesion PCI in the target vessel within 12 months of the baseline procedure.&#xD;
&#xD;
          4. History of stent thrombosis.&#xD;
&#xD;
          5. Cardiogenic shock (defined as persistent hypotension (systolic blood pressure &lt;90&#xD;
             mm/Hg for more than 30 minutes) or requiring pressors or hemodynamic support,&#xD;
             including IABP.&#xD;
&#xD;
          6. Subject is intubated.&#xD;
&#xD;
          7. Known LVEF &lt;30%.&#xD;
&#xD;
          8. Relative or absolute contraindication to DAPT for 12 months (including planned&#xD;
             surgeries that cannot be delayed)&#xD;
&#xD;
          9. Subject has an indication for chronic oral anticoagulant treatment (with either&#xD;
             vitamin K antagonists or novel anticoagulants - NOACs)&#xD;
&#xD;
         10. Calculated creatinine clearance &lt;30 mL/min using Cockcroft-Gault equation.&#xD;
&#xD;
         11. Hemoglobin &lt;10 g/dL.&#xD;
&#xD;
         12. Platelet count &lt;100,000 cells/mm3 or &gt;700,000 cells/mm3.&#xD;
&#xD;
         13. White blood cell (WBC) count &lt;3,000 cells/mm3.&#xD;
&#xD;
         14. Clinically significant liver disease.&#xD;
&#xD;
         15. Active peptic ulcer or active bleeding from any site.&#xD;
&#xD;
         16. Bleeding from any site within the prior 8 weeks requiring active medical or surgical&#xD;
             attention.&#xD;
&#xD;
         17. If femoral access is planned, significant peripheral arterial disease which precludes&#xD;
             safe insertion of a 6F sheath.&#xD;
&#xD;
         18. History of bleeding diathesis or coagulopathy or will refuse blood transfusions.&#xD;
&#xD;
         19. Cerebrovascular accident or transient ischemic attack within the past 6 months, or any&#xD;
             permanent neurologic defect attributed to CVA.&#xD;
&#xD;
         20. Known allergy to the study stent components e.g. cobalt, nickel, chromium, Carbosil®,&#xD;
             PBMA, or limus drugs (ridaforolimus, zotarolimus, tacrolimus, sirolimus, everolimus,&#xD;
             or similar drugs or any other analogue or derivative or similar compounds).&#xD;
&#xD;
         21. Known allergy to protocol-required concomitant medications such as aspirin, or DAPT&#xD;
             (Drugs that inhibit P2Y12 such as clopidogrel and prasugrel), or heparin, or iodinated&#xD;
             contrast that cannot be adequately pre-medicated.&#xD;
&#xD;
         22. Any co-morbid condition that may cause non-compliance with the protocol (e.g.&#xD;
             dementia, substance abuse, etc.) or reduced life expectancy to &lt;24 months (e.g.&#xD;
             cancer, severe heart failure, severe lung disease).&#xD;
&#xD;
         23. Patient is participating in any other investigational drug or device clinical trial&#xD;
             that has not reached its primary endpoint, or plans to participate in any clinical&#xD;
             trial.&#xD;
&#xD;
         24. Women who are pregnant or breastfeeding (women of child-bearing potential, defined as&#xD;
             females of childbearing potential if they have not undergone a permanent contraceptive&#xD;
             operation or they are not postmenopausal, must have a negative pregnancy test within&#xD;
             one week before treatment. Permanent contraceptive operation is defined as:&#xD;
             hysterectomy, hysterosalpingectomy, or bilateral oophorectomy. The status of a female&#xD;
             should be considered as postmenopausal when she has not had a period for 12&#xD;
             consecutive months without an alternative medical cause).&#xD;
&#xD;
         25. Women who intend to become pregnant within 12 months after the baseline procedure&#xD;
             (women of child-bearing potential who are sexually active must agree to use a reliable&#xD;
             method of contraception from the time of screening through 12 months after the&#xD;
             baseline procedure).&#xD;
&#xD;
         26. Patient has received an organ transplant or is on a waiting list for an organ&#xD;
             transplant.&#xD;
&#xD;
         27. Patient is receiving or scheduled to receive chemotherapy within 30 days before or any&#xD;
             time after the baseline procedure.&#xD;
&#xD;
         28. Patient is receiving oral or intravenous immunosuppressive therapy or has known&#xD;
             life-limiting immunosuppressive or autoimmune disease (e.g., HIV). Corticosteroids are&#xD;
             allowed.&#xD;
&#xD;
             Angiographic Exclusion Criteria (visual estimate):&#xD;
&#xD;
         29. Target lesions in more than two (2) major coronary arteries (i.e., two of LAD, LCX,&#xD;
             RCA) and their respective branches (the Ramus Intermedius is defined as a branch of&#xD;
             the LCX).&#xD;
&#xD;
         30. More than two target lesions per target vessel are planned (two lesions separated by&#xD;
             less than 10 mm that can be covered by a single stent are considered as one lesion).&#xD;
&#xD;
         31. More than 100 mm length of planned study stenting in the entire coronary tree.&#xD;
&#xD;
         32. Occlusive thrombus and/or a thrombus requiring thrombectomy in a target vessel.&#xD;
&#xD;
         33. Unprotected left main lesions ≥30%, or planned unprotected left main intervention.&#xD;
&#xD;
         34. Ostial LAD or LCX lesions (stenting of any diseased segment within 5 mm of the&#xD;
             unprotected left main coronary artery).&#xD;
&#xD;
         35. Bifurcation lesions with planned dual stent implantation.&#xD;
&#xD;
         36. Stenting of lesions due to DES restenosis.&#xD;
&#xD;
         37. Another lesion in a target or non-target vessel (including all side branches) is&#xD;
             present that requires or has a high probability of requiring PCI within 12 months&#xD;
             after the baseline procedure.&#xD;
&#xD;
         38. Target lesion exists in bypass graft vessels.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shigeru Saito, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shonan Kamakura General Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Seiji Yamazaki, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sapporo Higashi Tokushukai Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Atsuo Namiki, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kanto Rosai Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Yoshisato Shibata, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Miyazaki Medical Association Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Satoru Otsuji, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Higashi Takarazuka Satoh Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Shigeu Nakamura, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kyoto Katsura Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Akihiko Takahashi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Takahashi Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Tomohiro Kawasaki, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shin Koga Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Yasuhiro Makita, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Hakodate Hokkaido</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Takeshi Serikawa, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Saiseikai Fukuoka General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Shonan Kamakura General</name>
      <address>
        <city>Kamakura-City</city>
        <state>Kanagawa</state>
        <zip>247-8533</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>July 3, 2016</study_first_submitted>
  <study_first_submitted_qc>July 7, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 12, 2016</study_first_posted>
  <results_first_submitted>August 16, 2020</results_first_submitted>
  <results_first_submitted_qc>September 3, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">September 24, 2020</results_first_posted>
  <last_update_submitted>September 3, 2020</last_update_submitted>
  <last_update_submitted_qc>September 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>September 18, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/17/NCT02828917/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>August 8, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/17/NCT02828917/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>MedJ-01 Drug Eluting Stent</title>
          <description>MedJ-01 Ridaforolimus eluting coronary stent system&#xD;
MedJ-01 Ridaforolimus Eluting Coronary Stent System</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="104"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="104"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>MedJ-01 Drug Eluting Stent</title>
          <description>MedJ-01 Ridaforolimus eluting coronary stent system&#xD;
MedJ-01 Ridaforolimus Eluting Coronary Stent System</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="104"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="104"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="104"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Japan</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="104"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Target Lesion Failure (TLF)</title>
        <description>TLF is defined as the composite of cardiac death, target vessel-related myocardial infarction, or ischemia-driven target lesion revascularization.</description>
        <time_frame>12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>MedJ-01 Drug Eluting Stent</title>
            <description>MedJ-01 Ridaforolimus eluting coronary stent system&#xD;
MedJ-01 Ridaforolimus Eluting Coronary Stent System</description>
          </group>
        </group_list>
        <measure>
          <title>Target Lesion Failure (TLF)</title>
          <description>TLF is defined as the composite of cardiac death, target vessel-related myocardial infarction, or ischemia-driven target lesion revascularization.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="104"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Device Success at Time of Baseline Procedure</title>
        <time_frame>30 days, 6 months, and 1, 2, 3, 4 and 5 years</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Lesion Success at Time of Baseline Procedure</title>
        <time_frame>30 days, 6 months, and 1, 2, 3, 4 and 5 years</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Procedure Success at Time of Baseline Procedure</title>
        <time_frame>30 days, 6 months, and 1, 2, 3, 4 and 5 years</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>TLF</title>
        <time_frame>30 days, 6 months, and 2, 3, 4 and 5 years</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Major Adverse Cardiac Events (MACE)</title>
        <description>MACE is the composite rate of cardiac death, any MI or ischemia-driven TLR</description>
        <time_frame>30 days, 6 months, and 1, 2, 3, 4 and 5 years</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Target Vessel Failure (TVF)</title>
        <description>the composite rate of death, target vessel related MI or ischemia-driven TVR</description>
        <time_frame>30 days, 6 months, and 1, 2, 3, 4 and 5 years</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>All-cause Mortality</title>
        <time_frame>30 days, 6 months, and 1, 2, 3, 4 and 5 years</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cardiac Death</title>
        <time_frame>30 days, 6 months, and 1, 2, 3, 4 and 5 years</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Myocardial Infarction</title>
        <time_frame>30 days, 6 months, and 1, 2, 3, 4 and 5 years</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Target Vessel Related MI</title>
        <time_frame>30 days, 6 months, and 1, 2, 3, 4 and 5 years</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ischemia-driven TLR</title>
        <time_frame>30 days, 6 months, and 1, 2, 3, 4 and 5 years</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ischemia-driven TVR</title>
        <time_frame>30 days, 6 months, and 1, 2, 3, 4 and 5 years</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Stent Thrombosis</title>
        <description>ARC definite and probable</description>
        <time_frame>30 days, 6 months, and 1, 2, 3, 4 and 5 years</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>The Investigator monitored the occurrence of adverse events or device deficiencies for each subject during the whole course of the trial, visits: baseline and post procedure, 30 days, 6 months, 1 year, 2 years, 3 years, 4 years and 5 years.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>MedJ-01 Drug Eluting Stent</title>
          <description>MedJ-01 Ridaforolimus eluting coronary stent system&#xD;
MedJ-01 Ridaforolimus Eluting Coronary Stent System</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="104"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>cardiac disorders</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="104"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Eye disorders</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="104"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal disorders</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="104"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>General disorders and administration site conditions</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="104"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Injury, poisoning and procedural complications</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="104"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Neoplasms benign, malignant and unspecified</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="104"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal and urinary disorders</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="104"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Skin and subcutaneous tissue disorders</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="104"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Vascular disorders</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="104"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="59" subjects_at_risk="104"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Blood and lymphatic system disorders</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="104"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac Disorders</sub_title>
                <counts group_id="E1" events="15" subjects_affected="15" subjects_at_risk="104"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Eye disorders</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="104"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal disorders</sub_title>
                <counts group_id="E1" events="20" subjects_affected="14" subjects_at_risk="104"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>General disorders and administration site conditions</sub_title>
                <counts group_id="E1" events="14" subjects_affected="12" subjects_at_risk="104"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatobiliary disorders</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="104"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infections and infestations</sub_title>
                <counts group_id="E1" events="20" subjects_affected="17" subjects_at_risk="104"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Injury, poisoning and procedural complications</sub_title>
                <counts group_id="E1" events="13" subjects_affected="11" subjects_at_risk="104"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Investigations</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="104"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Metabolism and nutrition disorders</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="104"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Musculoskeletal and connective tissue disorders</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="104"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</sub_title>
                <counts group_id="E1" events="5" subjects_affected="3" subjects_at_risk="104"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Nervous system disorders</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="104"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Psychiatric disorders</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="104"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal and urinary disorders</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="104"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Respiratory, thoracic and mediastinal disorders</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="104"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Skin and subcutaneous tissue disorders</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="104"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Vascular disorders</sub_title>
                <counts group_id="E1" events="8" subjects_affected="5" subjects_at_risk="104"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dina Kofler, VP Clinical Affairs</name_or_title>
      <organization>Medinol</organization>
      <phone>+97237679032</phone>
      <email>dinak@medinol.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

